Novavax

The future looks very bullish for this vaccine specialist. At the beginning of 2020, Novavax (NASDAQ:NVAX) had a valuation of $4 a share. Six months later, the company's stock sells for $47 a share. That's a dramatic shift in perception of value. What's the stock market seeing now that it didn't see in January? In a…

Novavax Inc said on Wednesday it would acquire a manufacturing plant in the Czech Republic for $167 million as the drug developer looks to boost capacity to produce its COVID-19 vaccine candidate. Novavax, one of the handful of companies aiming to develop a vaccine for COVID-19, said on Monday that it enrolled its first participant…

No results matched your search Stock Markets4 hours ago (May 26, 2020 09:14AM ET) © Reuters. By Geoffrey Smith  Investing.com -- Stocks in focus in premarket trade on Tuesday, May 26th. The broader market is set to open sharply higher amid hopes for a quick economic rebound as the coronavirus recedes in the northern hemisphere.…

Novavax Inc said on Monday it has started the Phase 1 clinical trial of a novel coronavirus vaccine candidate and has enrolled the trial’s first participants, with preliminary results slated for July. Subscribe: http://smarturl.it/reuterssubscribeReuters brings you the latest business, finance and breaking news video from around the globe. Our reputation for accuracy and impartiality is…

Dr. Sonia Macieiewski (R) and Dr. Nita Patel, Director of Antibody discovery and Vaccine development, look at a sample of a respiratory virus at Novavax labs in Rockville, Maryland on March 20, 2020, one of the labs developing a vaccine for the coronavirus, COVID-19.Andrew Caballero-Reynolds | AFP | Getty ImagesNovavax said on Monday it has…